The pharmaceutical sector has experienced a year of heavy consolidations, with a record breaking M&A volume of $250bn in 2014. From a shareholder perspective this should, however, cause serious concern as the deals very rarely maximise the owner’s wealth. An illustration of this is the failed acquisition of AstraZeneca by US pharmaceutical giant Pfizer in spring 2014, when the British, despite strong strategic synergies, decided to reject an $117bn takeover bid, due to an insufficient price-offer.
This essay is going to critically evaluate the concepts of shareholder wealth creation, in light of appropriate evaluation methods for bids and the influence of capital structure. It will be concluded that information asymmetry was one of the core issues in the case, as both parties ultimately misestimated potential synergies. Moreover, it is argued that irrational decisions, made by executive, can significantly impact and eventually destroy shareholder value.
Table of Contents
1. Creation of Shareholder Value in the Pfizer-AstraZeneca Deal
2. Valuation of Bids
3. Capital Structure
4. Value-Creation in M&As
5. Conclusion
Objectives and Key Themes
The primary objective of this essay is to critically evaluate the mechanisms of shareholder wealth creation within the context of the failed Pfizer-AstraZeneca acquisition. It addresses the central research question of how valuation methods and capital structure decisions influence the success or failure of such large-scale pharmaceutical mergers, specifically investigating whether information asymmetry and executive decision-making hinder value maximisation.
- Theoretical frameworks of firm valuation (Market-based, Income-based, and NAV approaches).
- Capital structure theories and the impact of debt-financing on shareholder wealth.
- Short-term vs. long-term market performance implications of M&A activities.
- The role of information asymmetry and management incentives in takeover negotiations.
- Critical analysis of the pharmaceutical industry's consolidation trends.
Excerpt from the Book
Valuation of Bids
One of the key challenges and, after all, the insurmountable hurdle of the Pfizer-AstraZeneca deal was the agreeing on a takeover price (Pettypiece, 2014). From a shareholder perspective, evaluating the bids for shares is crucial as it is ultimately their risk, savings and value that is affected by a potential merger (Arnold, 2013, p. 366). The literature generally presents market-based, income-based and net-asset (NAV) valuation approaches in this context (Bernstrom, 2014).
Provided that Fama’s (1970) Efficient Market Hypotheses holds true and shares constantly reflect the value of a firm, market-based valuations, in terms of market capitalisation, seems to be the most straightforward assessment technique. However, as argued by Malkiel (2003, 2005) and Summers (1986), markets are rarely entirely rational and pricing is therefore often inadequate. In this context the price-earnings ratio (PER), as an advanced evaluation model, includes future market returns (Basu, 1977; Malkiel, 2003). Shareholders can employ the PER in order to estimate the target’s total equity value by re-estimating future earnings and multiplying them with benchmark PE-ratios (Sudarsanam, 2010, p. 429). Myers (1984b), however, raises fundamental concerns with the accurate forecasting of future earnings, which, in fact, seemed to be one of the major hurdles in the Pfizer-AstraZeneca case, bearing in mind that long-term estimates are particularly challenging in the pharmaceutical environment (Armstrong & Staley, 2014).
Summary of Chapters
Creation of Shareholder Value in the Pfizer-AstraZeneca Deal: This introductory chapter outlines the consolidation trends in the pharmaceutical sector and introduces the failed acquisition as a case study to investigate shareholder wealth creation.
Valuation of Bids: This section critically examines various valuation techniques, such as PER, DCF, and NAV, and highlights how information asymmetry between parties complicated the agreement on a takeover price.
Capital Structure: This chapter analyzes the controversy surrounding debt-financing and leverage, testing traditional theories like the Trade-Off and Pecking Order against Pfizer's financing plans.
Value-Creation in M&As: This analysis focuses on empirical evidence regarding short-term and long-term stock performances to determine whether M&A activities generally create or destroy shareholder value.
Conclusion: The final chapter synthesizes the findings, concluding that information asymmetry and irrational executive decisions were key drivers in the deal's failure, while noting the complexity of wealth maximisation.
Keywords
Shareholder Value, M&A, Pfizer, AstraZeneca, Valuation, Capital Structure, Information Asymmetry, Efficient Market Hypothesis, Pharmaceutical Industry, Debt-Financing, Merger, Acquisition, Synergies, Wealth Maximisation, Discounted Cash Flow.
Frequently Asked Questions
What is the fundamental focus of this academic essay?
The essay explores the dynamics of shareholder value creation by analyzing the specific circumstances of the failed 2014 takeover attempt of AstraZeneca by Pfizer.
What are the primary thematic pillars of the research?
The research focuses on the intersection of corporate valuation methodologies, the implications of capital structure choices, and the empirical outcomes of merger and acquisition strategies.
What is the core research objective?
The objective is to evaluate why the Pfizer-AstraZeneca merger failed to gain approval, specifically looking at how valuation discrepancies and financing strategies impacted the perceived value for shareholders.
Which academic methods are utilized in this work?
The author employs a critical review of existing financial literature, including market-based, income-based, and asset-based valuation models, alongside an analysis of event-driven stock market reactions.
What topics are covered in the main body of the text?
The main body covers the theoretical foundations of firm valuation, the debate over optimal capital structure, and an empirical assessment of whether M&As typically deliver the promised shareholder value.
Which keywords best define this study?
Key terms include Shareholder Value, M&A, Valuation, Capital Structure, Information Asymmetry, and Pharmaceutical Industry.
How did information asymmetry influence the Pfizer-AstraZeneca outcome?
The essay argues that information asymmetry regarding the future potential of the R&D pipeline led to a significant price gap, preventing the parties from reaching a mutually acceptable takeover agreement.
What does the study conclude regarding the long-term effects of pharmaceutical M&As?
The study concludes that, in the long run, large-scale pharmaceutical consolidations frequently struggle to create value for shareholders, as anticipated synergies are often overstated and offset by internal restructuring costs.
- Arbeit zitieren
- Markus Bäder (Autor:in), 2015, Creation of Shareholder Value in the Pfizer-AstraZeneca Deal, München, GRIN Verlag, https://www.grin.com/document/323354
